UBS launches SMID cap biotechs with cancer, autoimmunity in focus

Like
Comment
Favorite

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

seekingalpha10-25

mbbirdy With a focus on cancer and autoimmune conditions, UBS has launched its coverage of 13 small and mid-cap biotechs, noting that stocks with competitive advantages, such as best-in-class or first...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2478990356?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/169994549/image_169994549.jpg?io=getty-c-w750","is_english":true,"pubTime":"2024-10-25 03:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478990356","market":"other","top_or_hot":-1,"title":"UBS launches SMID cap biotechs with cancer, autoimmunity in focus","media":"seekingalpha","content":"<div>\n<p>mbbirdy With a focus on cancer and autoimmune conditions, UBS has launched its coverage of 13 small and mid-cap biotechs, noting that stocks with competitive advantages, such as best-in-class or first...</p>\n\n<a href=\"https://seekingalpha.com/news/4201817-ubs-starts-smid-cap-biotechs-cancer-autoimmunity-focus\">Source Link</a>\n\n</div>\n","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS launches SMID cap biotechs with cancer, autoimmunity in focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS launches SMID cap biotechs with cancer, autoimmunity in focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-25 03:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4201817-ubs-starts-smid-cap-biotechs-cancer-autoimmunity-focus><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>mbbirdy With a focus on cancer and autoimmune conditions, UBS has launched its coverage of 13 small and mid-cap biotechs, noting that stocks with competitive advantages, such as best-in-class or first...</p>\n\n<a href=\"https://seekingalpha.com/news/4201817-ubs-starts-smid-cap-biotechs-cancer-autoimmunity-focus\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CATX","symbol_name":"Perspective Therapeutics","start_time":0,"source_url":"https://seekingalpha.com/news/4201817-ubs-starts-smid-cap-biotechs-cancer-autoimmunity-focus","article_id":"2478990356","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/169994549/image_169994549.jpg?io=getty-c-w750"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478990356","pubTimestamp":1729798352,"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"mbbirdy With a focus on cancer and autoimmune conditions, UBS has launched its coverage of 13 small and mid-cap biotechs, noting that stocks with competitive advantages, such as best-in-class or first-in-class candidates, have underpinned its thesis. Out of 10 buy-rated stocks, analyst","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CATX":"Perspective Therapeutics","SNDX":"Syndax Pharmaceuticals, Inc. ","BK4011":"建筑材料","IDYA":"IDEAYA Biosciences","BK4139":"生物科技","IOVA":"Iovance Biotherapeutics, Inc.","SMID":"SMITH-MIDLAND CORP"},"translate_title":"瑞银推出SMID cap biotechs，重点关注癌症和自身免疫","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMID":1,"CATX":0.9,"IDYA":0.9,"IOVA":0.9,"SNDX":0.9},"content_text":"mbbirdy With a focus on cancer and autoimmune conditions, UBS has launched its coverage of 13 small and mid-cap biotechs, noting that stocks with competitive advantages, such as best-in-class or first-in-class candidates, have underpinned its thesis. Out of 10 buy-rated stocks, analyst","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}